Results 161 to 170 of about 18,682 (303)

Combined nonmyeloablative total lymphoid irradiation and low-dose total body irradiation enhances donor chimerism and leads to islet allograft acceptance. [PDF]

open access: yesAm J Transplant
Pathak S   +16 more
europepmc   +1 more source

Predictive value of MRD monitoring by BCR clonality in the ZUMA‐7 randomized clinical trial for CAR T therapy in r/r lymphoma

open access: yes
British Journal of Haematology, EarlyView.
Brodie Miles   +5 more
wiley   +1 more source

Plasma Proteomic Analysis Reveals Complement System Changes in Irradiated Female BALB/c Mice during Mammary Carcinogenesis. [PDF]

open access: yesCancer Res Commun
Akbarzadeh T   +8 more
europepmc   +1 more source

Gene Therapy and Gene Editing in Type 1 Diabetes: CRISPR‐Based β‐Cell Replacement and Treg Immune Modulation Approaches

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disease marked by the destruction of pancreatic β‐cells, resulting in lifelong dependence on exogenous insulin. Despite advances in insulin delivery and glucose monitoring technologies, patients remain at risk for acute and long‐term complications, underscoring the need for ...
Tzu‐Min Lin   +5 more
wiley   +1 more source

Emerging Techniques in Minimally Invasive Surgery in Hematologic Malignancies

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Hematologic malignancies represent the most common cancers in children. While the mainstays of treatment are chemotherapy and potentially hematopoietic stem cell transplant, minimally invasive surgery (MIS) has a role in the diagnosis and management of complications related both to disease and therapy as well as common pediatric surgical ...
Alejandro Chara   +3 more
wiley   +1 more source

Loncastuximab Tesirine in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: Evidence and Practical Guidance From Italian Clinical Experience

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Patients with relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) who progress to the third‐line setting face a lack of standardized treatment, despite the presence of multiple available therapies. In this context, antibody–drug conjugates represent a relatively new class of anticancer agents; among them, loncastuximab tesirine is ...
Francesca Bonello   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy